Download office memorandum dt 25-03-2022, link given below.

New Delhi: In what can be termed as the highest price hike ever, the National Pharmaceutical Pricing Authority (NPPA), the apex price regulatory body has announced a price hike of 10.76607% for scheduled drugs-which are under price control vide its office memorandum dt 25-03-2022.

Download office memorandum dt 25-03-2022

Confirmation to this effect was recently given by the NPPA, Department of Pharmaceuticals, in its recently office memorandum.

The move comes the basis of Wholesale Price Index (WPI) data provided by the Office of the Economic Advisor, Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry whereby the annual change in the WPI works out as 10.76607% during the calendar year 2021 over the corresponding period in 2020.

Click for more articles on NPPA

National Pharmaceutical Pricing Authority (NPPA) under the aegis of the Department of Pharmaceuticals fixes the ceiling price of scheduled medicines as per provisions of the Drugs (Prices Control) Order, 2013. 

NPPA has fixed ceiling prices of 886 scheduled formulations & 4 scheduled medical devices and fixed retail prices of 1,817 new drugs. The prices of these formulations are revised by the NPPA based on the WPI each year

In case of non-scheduled medicines, a manufacturer is at liberty to fix the Maximum Retail Price (MRP) launched by it, but is not allowed to increase the MRP of such formulations by more than 10% per annum.

The move will spell out costlier essential medicines for the people as majority of the essential drugs have their prices controlled by the government via their inclusion in the National List of Essential Medicines (NLEM).

NLEM lists drugs used to treat common conditions such as fever, infection, heart disease, hypertension, skin diseases and anaemia, among others.

Also read

Latest on National Pharmaceutical Pricing Authority (NPPA)

Latest notifications – DPCO / NPPA

Latest Notifications: EC Act (Essential Commodities Act)

FAQs – On DPCO: Drugs (Prices Control) Order, 2013

Maharashtra FDA to get 15 new Asstt. Commissioners to combat impending...

USFDA probe of Abbott facility finds quality control issues

DCGI calls on stakeholders to initiate Clinical Trials early

USFDA gives nod to Lupin for Sildenafil for oral suspension

NPPA’s expert panel recommends retail price for FDCs of anti-diabetic linagliptin

DCGI gives nod to Phase-3 Clinical Trial of Covovax Vaccine

Drug recall: This drug recalled due to detection of NDMA

Drug recall: Some lots of Blood Pressure Drug due to this…

CDSCO approves Sputnik Light vaccine for manufacture for sale in India

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/03/27/nppa-allows-price-hike-of-essential-medicines-by-more-than-10-percent/